Immage Net Income Applicable To Common Shares from 2010 to 2025

IMMG Stock  USD 0.0001  0.00  0.00%   
Immage Biotherapeutics' Net Loss is decreasing over the last several years with slightly volatile swings. Net Loss is estimated to finish at about -185.1 K this year. Net Loss is the net income that remains after preferred dividends have been deducted, available to common shareholders. View All Fundamentals
 
Net Loss  
First Reported
2010-12-31
Previous Quarter
-194.8 K
Current Value
-185.1 K
Quarterly Volatility
91.5 K
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Immage Biotherapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Immage Biotherapeutics' main balance sheet or income statement drivers, such as Discontinued Operations of 0.0, Interest Expense of 0.0 or Selling General Administrative of 186.3 K, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 7.0E-4. Immage financial statements analysis is a perfect complement when working with Immage Biotherapeutics Valuation or Volatility modules.
  
Build AI portfolio with Immage Stock
Check out the analysis of Immage Biotherapeutics Correlation against competitors.

Currently Active Assets on Macroaxis

When determining whether Immage Biotherapeutics is a strong investment it is important to analyze Immage Biotherapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Immage Biotherapeutics' future performance. For an informed investment choice regarding Immage Stock, refer to the following important reports:
Check out the analysis of Immage Biotherapeutics Correlation against competitors.
You can also try the Stocks Directory module to find actively traded stocks across global markets.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Immage Biotherapeutics. If investors know Immage will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Immage Biotherapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(0.01)
Return On Assets
(4.96)
Return On Equity
(11.34)
The market value of Immage Biotherapeutics is measured differently than its book value, which is the value of Immage that is recorded on the company's balance sheet. Investors also form their own opinion of Immage Biotherapeutics' value that differs from its market value or its book value, called intrinsic value, which is Immage Biotherapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Immage Biotherapeutics' market value can be influenced by many factors that don't directly affect Immage Biotherapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Immage Biotherapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Immage Biotherapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Immage Biotherapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.